Combined treatment with ipilimumab and intratumoral interleukin-2 in pretreated patients with stage IV melanoma-safety and efficacy in a phase II study - PubMed (original) (raw)

Clinical Trial

Combined treatment with ipilimumab and intratumoral interleukin-2 in pretreated patients with stage IV melanoma-safety and efficacy in a phase II study

Benjamin Weide et al. Cancer Immunol Immunother. 2017 Apr.

Abstract

Treatment of advanced melanoma patients with ipilimumab results in improved survival. However, only about 20% of treated patients experience long-term benefit. Combining treatment of ipilimumab with other drugs may improve immune activation and potentially enhance clinical efficacy. The aims of the phase II clinical trial reported here were to investigate tolerability and efficacy of a combined immunotherapeutic strategy comprising standard systemic ipilimumab at 3 mg/kg four times at 3-week intervals and intratumorally injected IL-2 at 9 MIU daily twice weekly for four weeks in pretreated melanoma patients with distant metastasis. The primary endpoint was the disease control rate according to immune-related response criteria at week 12; tolerability according to Common Terminology Criteria for Adverse Events criteria was secondary endpoint. No objective responses were observed in the 15 enrolled patients. Three patients had stable disease 12 weeks after starting treatment, yielding a disease control rate of 20%. Tolerability of this combination treatment was acceptable. Observed adverse events were those expected from the respective monotherapies. Autoimmune colitis was observed in two patients. Grade III/IV adverse events were observed in 40% of patients, and no treatment-related deaths occurred. Thus, this combined immunotherapy is associated with adverse events similar to those associated with the respective monotherapies. However, this study does not provide any evidence of improved efficacy of the combination over ipilimumab alone.

Keywords: Clinical trial; Interleukin-2; Ipilimumab; Melanoma.

PubMed Disclaimer

Conflict of interest statement

B Weide reports receiving commercial research grants from Bristol–Myers Squibb (BMS) and MSD Sharp and Dohme (MSD) and reports receiving travel/accommodations/expenses from BMS, MSD, Roche, Amgen, Philogen, Curevac and compensated advisory services for MSD, BMS, Philogen and Curevac. C. Garbe reports receiving honoraria from BMS, MSD, Amgen, Novartis, Roche, GlaxoSmithKline (GSK) and reports receiving commercial research grants from MSD, BMS, Roche, GSK. T.K Eigentler reports receiving honoraria from BMS, MSD, Roche and Novartis, travel/accommodations/expenses from BMS and is a consultant/advisory board member for BMS. No potential conflicts of interest were disclosed by the other authors.

Figures

Fig. 1

Fig. 1

Overall survival of the entire cohort. Kaplan–Meier analysis representing overall survival following combined immunotherapy comprising intratumoral IL-2 and systemic ipilimumab treatment for 15 included patients. Censored patients are indicated by vertical lines

Similar articles

Cited by

References

    1. Atkins MB, Lotze MT, Dutcher JP, Fisher RI, Weiss G, Margolin K, et al. High-dose recombinant interleukin 2 therapy for patients with metastatic melanoma: analysis of 270 patients treated between 1985 and 1993. J Clin Oncol. 1999;17(7):2105–2116. doi: 10.1200/JCO.1999.17.7.2105. - DOI - PubMed
    1. Vlasveld LT, Horenblas S, Hekman A, Hilton AM, Dubbelman AC, Melief CJ, et al. Phase II study of intermittent continuous infusion of low-dose recombinant interleukin-2 in advanced melanoma and renal cell cancer. Ann Oncol. 1994;5(2):179–181. doi: 10.1093/oxfordjournals.annonc.a058774. - DOI - PubMed
    1. Hauschild A, Weichenthal M, Balda BR, Becker JC, Wolff HH, Tilgen W, et al. Prospective randomized trial of interferon alfa-2b and interleukin-2 as adjuvant treatment for resected intermediate- and high-risk primary melanoma without clinically detectable node metastasis. J Clin Oncol. 2003;21(15):2883–2888. doi: 10.1200/JCO.2003.07.116. - DOI - PubMed
    1. Radny P, Caroli UM, Bauer J, Paul T, Schlegel C, Eigentler TK, et al. Phase II trial of intralesional therapy with interleukin-2 in soft-tissue melanoma metastases. Br J Cancer. 2003;89(9):1620–1626. doi: 10.1038/sj.bjc.6601320. - DOI - PMC - PubMed
    1. Weide B, Derhovanessian E, Pflugfelder A, Eigentler TK, Radny P, Zelba H, et al. High response rate after intratumoral treatment with interleukin-2: results from a phase 2 study in 51 patients with metastasized melanoma. Cancer. 2010;116(17):4139–4146. doi: 10.1002/cncr.25156. - DOI - PubMed

Publication types

MeSH terms

Substances

LinkOut - more resources